Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ocera Therapeutics, a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases, has completed a $35.5 million series C financing from a syndicate of investors.
Subscribe to our email newsletter
To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners will take a seat on the Ocera board of directors representing Montagu Newhall Associates and the series C investors.
Laurent Fischer, co-founder, president and CEO of Ocera, said: “We are privileged to have attracted a syndicate of renowned investors with specific expertise in the gastrointestinal market as well as international and crossover investors and we welcome Linda Grais’s guidance as she joins our board of directors.”